Head Surgery

PRESS RELEASES

Cellastra announces 10M USD Series A capital call to support a US Phase 3 study of PXL01 in scar prevention after tendon/nerve injury repair.

A recently completed multi-center, double blind, placebo-controlled Phase 2 study in 138 patients showed promising results in prevention of dysfunctional scarring and restoration of nerve and tendon function


• First indication in prevention of post-surgical scarring and adhesions after tendon and nerve repair in hands, arms and feet. Other indications to follow

• Multicenter phase 3 study in US and Canada to begin in 2017and data expected 2020

• Low risk and low development costs. Seeking 10M USD from Venture Capital and private investors to cover costs from Year 1 to registration Year 3


San Francisco, CA, June 6, 2017. Cellastra, Inc., a developer of late stage pharmaceutical assets announced today that the company has initiated a 10M USD Series A capital call after completing the recently announced (May 11, 2017) co-development and licensing agreement with Promore Pharma AB, Stockholm, Sweden.

The agreement involves strategic collaboration for the global phase 3 clinical development of a proprietary therapeutic peptide, PXL01, and subsequent registration and commercialization in US and Canada. The agreement also gives Cellastra exclusive right to Promore’s intellectual property related to PXL01 for the North American territory.

Adhesions are common to all invasive surgical procedures, in particular after tendon injuries in the hand. Hand injuries usually affect young, active and otherwise healthy people and are often caused by sports, recreational injuries or work-related accidents.

Cellastra is preparing initiation of a phase 3 study at more than 20 hospitals in US and Canada using the PXL01, a disruptive peptide with promising effects to prevent scarring after surgery. PXL01 addresses the large unmet medical need that exists because 30-50 percent of sports and many work and home activity injuries involve tendons, all with substantial quality of life consequences and substantial cost of health care. An estimated more than 350,000 tendon and nerve repair procedures, many with a high risk of incapacitating post-surgical adhesions/scars, are conducted annually in North America. There are no pharmaceutical products available on the market to prevent adhesions and scars.

A recently published, double-blind, placebo-controlled study of PXL01 in 138 patients with hand flexor tendon injuries treated in Sweden, Denmark and Germany showed statistically significant improvement in four of five efficacy measures without safety concerns. The treatment is easily applied as a slow-release topical gel in the surgical area at the end of the surgical procedure. The project is also considered low risk and low cost due to ease of administration and monitoring with a great potential in new indications as scar tissue is formed in about 90 percent of surgeries.

About Cellastra Inc. (www.cellastra.com)

Cellastra Inc. is a private biotech firm in San Francisco, founded and managed by proven industry executives with a mission to develop first-in-class therapeutics and disruptive technologies that address serious unmet medical needs through partnerships designed to reduce risk and accelerate product development. Cellastra identifies and in-licenses assets, multiplying value by completing preclinical/clinical development via partnerships with world class institutions, then monetizes programs through partnering with pharmaceutical companies at relevant milestones. The initial portfolio focuses on tissue and tendon repair and a platform of collagen mimetic peptides for wound healing using proprietary stem cell, exosome and biomatrix combinations.

Contact

Karl L. Mettinger
President and CEO, Cellastra Inc
Tel: [+1] 844-890-6316

karl.mettinger@cellastra.com

Disruptive peptide found for the prevention of dysfunctional scarring while restoring nerve and tendon function after injury repair surgery


• Cellastra and Promore Pharma complete co-development agreement

• First indication in prevention of post-surgical scarring and adhesions after tendon and nerve repair in hands, arms and feet. Other indications to follow

• Cellastra to undertake clinical development, regulatory approval and commercialization in North America.

• Multicenter phase 3 study in US and Canada to begin in 2017


San Francisco, CA, May 11, 2017. Cellastra, Inc., a developer of late stage pharmaceutical assets announced today that the company has completed the previously announced (December 2016) co-development and licensing agreement with Promore Pharma AB, Stockholm, Sweden.

The agreement involves strategic collaboration for the global phase 3 clinical development of a proprietary therapeutic peptide, PXL01, and subsequent registration and commercialization in US and Canada. The agreement also gives Cellastra exclusive right to Promore’s intellectual property related to PXL01 for the North American territory.

“PXL01 is a disruptive peptide that can prevent dysfunctional scarring while restoring nerve and tendon function after injury repair surgery. It has the potential to become standard treatment in hospitals worldwide”, said Dr Karl Mettinger, co-founder President and CEO of Cellastra.

Adhesions are common to all invasive surgical procedures, in particular after tendon injuries in the hand. Hand injuries usually affect young, active and otherwise healthy people and are often caused by sports or recreational injuries or work-related accidents. These adhesions tend to cause reduced mobility and difficulties performing everyday work tasks and recreational activities that involve fine motor skills such as the use of machinery, computers, playing instruments and sports. The result may be a substantial and permanent impairment of quality of life. An estimated target market of more than 350,000 tendon and nerve repair procedures with a high risk of incapacitating post-surgical adhesions/scars are conducted annually in North America. There are no pharmaceutical products available on the market to prevent adhesions and scars. A recently published, double-blind, placebo-controlled study of PXL01 in 138 patients with hand flexor tendon injuries treated in Sweden, Denmark and Germany showed statistically significant improvement in four of five efficacy measures without safety concerns.

These results strongly suggest that scarring after other types of surgeries can also be prevented which may reduce risk of infertility, bowel obstruction after stomach surgeries and chronic pain after total knee replacement or back surgeries. Post-operative scar tissue formation occurs in about 90 percent of surgeries. With aging population and rising living standard in emerging markets the number of procedures is expected to grow significantly.

Cellastra has been scouting globally to identify breakthrough medical technologies and found what they were looking for in Sweden. The delegation from California made stops at leading industrial parks to identify the right project.
"What we found was a first-in-class drug, PXL01, and a phase 3 candidate ready to take on an untapped multibillion dollar market for post-operative fibrosis causing disfiguring or dysfunctional scar tissue or adherences in millions of patients", said Dr Alan Lewis, a biotech industry veteran and Chairman of the Board, Cellastra.

Cellastra is now preparing initiation of a phase 3 study at more than 20 hospitals in US and Canada using the molecule invented in Sweden with powerful effects to prevent scarring after surgery. PXL01 addresses the large unmet medical need that exists because 30-50 percent of sports and many work and home activity injuries involve tendons, all with substantial quality of life consequences and substantial cost of health care. The treatment is easily applied as a slow-release topical gel in the surgical area at the end of the surgical procedure.

"If we can prove the effect and benefit in hand surgery and subsequently other indications this may become a revolutionary new treatment addressing a huge unmet medical need and with a multibillion dollar market potential", explained Dr Mettinger.

About Cellastra Inc. (www.cellastra.com)

Cellastra Inc. is a private biotech firm in San Francisco, founded and managed by proven industry executives with a mission to develop first-in-class therapeutics and disruptive technologies that address serious unmet medical needs through partnerships designed to reduce risk and accelerate product development. Cellastra identifies and in-licenses assets, multiplying value by completing preclinical/clinical development via partnerships with world class institutions, then monetizes programs through partnering with pharmaceutical companies at relevant milestones. The initial portfolio focuses on tissue and tendon repair and a platform of collagen mimetic peptides for wound healing using proprietary stem cell, exosome and biomatrix combinations.

Contact

Karl L. Mettinger
President and CEO, Cellastra Inc
Tel: [+1] 844-890-6316

karl.mettinger@cellastra.com

 

Cellastra Inc. announces appointment of new board member: Brad Thompson, PhD, previous Chair of BIOTECanada

Canadian biotech veteran and CEO of Kickshaw Ventures Ltd. takes board position in San Francisco based Cellastra Inc. to help with fundraising, manufacturing and corporate development.
SAN FRANCISCO, CA, January 18, 2017 – Cellastra Inc., a late clinical stage developer of pharmaceutical assets, today announced the appointment of Brad Thompson, PhD as a new member of the company’s board of directors. “This is a timely and important addition to our board as we recently announced the signing of a term sheet towards a strategic collaboration with Promore Pharma for the Phase III clinical development of PXL01” said Karl L Mettinger, MD, PhD, Cellastra’s President and CEO. “We are preparing initiation of the US Phase 3 study later this year for subsequent registration and marketing in the US and Canada.” “We welcome Dr Thompson to our board to strengthen our fundraising, manufacturing and corporate development,” said Alan Lewis, PhD, Chairman of the Board of Cellastra.

The US registrations study funded by Cellastra targets a first indication of prevention of post-surgical adhesions after tendon- and nerve-repair procedures in the hand, arm and foot. Adhesions frequently occur during the healing process, when scar tissue forms and connects tendons to the surrounding tendon sheath, thereby impeding normal tendon function. PXL01 addresses the large unmet medical need that exists because 30-50 percent of sports and many work and home activity injuries involve tendons, all with substantial quality of life consequences and substantial cost of health care.

“I congratulate the Cellastra team to having found this unique project, a potential jewel,” said Brad Thompson, PhD. “It is rare that you can start your involvement with a privately held company when it is entering a Phase 3 study that has double blinded, randomized, placebo controlled Phase 2 data from 138 patients showing not only promising efficacy, but in fact significant benefit in 4 of 5 clinically meaningful endpoints and no safety concern in an area of great unmet need.”

PXL01 has been shown to limit the production of inflammatory markers and to down-regulate secretion of Plasminogen Activator Inhibitor 1 (PAI-1), considered reflecting important mechanisms in the cause of scarring and adhesions. 

Dr. Thompson, Ph.D., CEO and co-founder of Kickshaw Ventures, most recently served as a Director and the Chairman of BIOTECanada and as Executive Chairman, CEO and President of Oncolytics Biotech Inc.He started his career in biotech as Head of Biotechnology at The Alberta Research Council where he was responsible for GMP manufacturing for biologics as well held a variety of other positions from 1983 to May 1994. He has also served as a Director of numerous public and private biotech companies.

About Cellastra Inc. (www.cellastra.com)

Cellastra Inc. is a private biotech firm in San Francisco, founded and managed by proven industry executives with a mission to develop first-in-class therapeutics and disruptive technologies that address serious unmet medical needs through partnerships designed to reduce risk and accelerate product development. Cellastra identifies and in-licenses assets, multiplying value by completing preclinical/clinical development via partnerships with world class institutions, then monetizes programs through partnering with pharmaceutical companies at relevant milestones. The initial portfolio focuses on tissue and tendon repair and a platform of collagen mimetic peptides for wound healing using proprietary stem cell, exosome and biomatrix combinations.

Contact

Karl L. Mettinger
President and CEO, Cellastra Inc
Tel: [+1] 844-890-6316

karl.mettinger@cellastra.com

 

Promore Pharma and Cellastra Inc. announce Phase III clinical collaboration to develop therapeutic peptide PXL01 for the US market

PXL01 first indication targets major unmet need for prevention of post-surgical adhesions after tendon- and nerve-repair procedures.
STOCKHOLM, SWEDEN and SAN FRANCISCO, CA, December 21, 2016 – Promore Pharma, a specialist biopharmaceutical developer of therapeutic peptides, and Cellastra Inc., a clinical stage developer of pharmaceutical assets, today announced the signing of a term sheet, towards a strategic collaboration for the Phase III clinical development of PXL01 and subsequent registration and marketing in the US and Canada.

"This co-development initiative for PXL01 in the US market is pivotal to our strategic approach and Cellastra is an ideal partner for us,” said Jonas Ekblom, President of Promore Pharma, “Together we will deploy our combined development capabilities and networks to expedite the development of this first-in-class pharmaceutical product for the North American market.”
The collaboration will target a first indication of prevention of post-surgical adhesions after tendon- and nerve-repair procedures in the hand, arm and foot. Adhesions frequently occur during the healing process, when scar tissue forms and connects tendons to the surrounding tendon sheath, thereby impeding normal tendon function.

Adhesions are common to all invasive surgical procedures, in particular after tendon injuries in the hand. Hand injuries usually affect young, active and otherwise healthy people and are often caused by sports or recreational injuries or work-related accidents. These adhesions tend to cause reduced mobility and difficulties performing everyday work task and recreational activities that involve fine motor skills such as the use of machinery, computers, playing instruments and sports. The result may be a substantial and permanent impairment of quality of life. An estimated target market of more than 350,000 tendon and nerve repair procedures with a high risk of incapacitating post-surgical adhesions/scars are conducted annually in North America. There are no pharmaceutical products available on the market to prevent adhesions and scars.

“PXL01 is an advanced clinical-stage asset with a perfect fit for Cellastra’s strategy around first- and best-in class products for tissue repair and wound healing – the treatment focus-area where our US development expertise can be leveraged optimally,” commented Karl Mettinger, co-founder, President and CEO, Cellastra Inc.

“PXL01 addresses the large unmet medical need that exists because 30-50 percent of sports and many work and home activity injuries involve tendons, all with substantial quality of life consequences and substantial cost of health care,” said Professor Christopher H. Evans, Rochester, Maurice Müller Professor of Orthopaedic Surgery Emeritus, Harvard Medical School. He is a new member of the Cellastra Scientific Advisory Board and senior author of a recent review publication of new treatment modalities for tendon repair.

Promore Pharma, which discovered and developed PXL01, has reported promising safety and efficacy results in a peer-reviewed publication of a Phase IIb prospective, randomized, placebo controlled, double-blind clinical trial involving 138 patients undergoing flexor tendon repair surgery. This proprietary product candidate is based on a human peptide sequence that is part of the innate immune system and found to have potent anti-infective, anti-inflammatory, and immunomodulatory effects. PXL01 has been shown to limit the production of inflammatory markers and to down-regulate secretion of Plasminogen Activator Inhibitor 1 (PAI-1), considered to reflect important mechanisms in the cause of scarring and adhesions.

Deal terms of the collaboration have not been disclosed.

About Promore Pharma (www.promorepharma.com)

Promore Pharma, is a biopharmaceutical company specialized in the development of therapeutic peptides for local application in advanced wound care. The company’s vision is to develop a portfolio of unique development programs representing high medical value in advanced wound- and skin care that ultimately, through global partnerships, will result in first-in-class products. The current development pipeline includes several therapeutic peptides of which two programs are in clinical development, with potential for use in several medical applications. Rosetta Capital, Midroc New Technology and PharmaResearch Products Ltd are the main investors in Promore Pharma, which is affiliated with Lipopeptide AB.

About Cellastra Inc. (www.cellastra.com)

Cellastra Inc. is a private biotech firm in San Francisco, founded and managed by proven industry executives with a mission to develop first-in-class therapeutics and disruptive technologies that address serious unmet medical needs through partnerships designed to reduce risk and accelerate product development. Cellastra identifies and in-licenses assets, multiplying value by completing preclinical/clinical development via partnerships with world class institutions, then monetizes programs through partnering with pharmaceutical companies at relevant milestones. The initial portfolio focuses on tissue and tendon repair and a platform of collagen mimetic peptides for wound healing using proprietary stem cell, exosome and biomatrix combinations.

Contact

Jonas Ekblom
President, Promore Pharma
Tel: [+1] 714 369 0478
jonas.ekblom@promorepharma.com

Karl L. Mettinger
President and CEO, Cellastra Inc
Tel: [+1] 844-890-6316

karl.mettinger@cellastra.com

 

 

Cellastra, Inc. appoints new members to the Management Team and Scientific Advisory Board

New team members are industry or academic research veterans with a long and successful track record of developing innovative products to meet unmet needs in transplantation, tissue repair, and wound healing.

December 15, 2016, San Francisco, CA -- Cellastra, Inc., a pioneering cellular therapeutics and regenerative medicine company, today announced the appointment of Dr Henrik Kulmala, PhD, as Senior Vice President Product Development and Regulatory Affairs. Furthermore, Professor Folke Sjoberg, MD, PhD, and Professor Christopher H Evans, have been appointed as members of the Scientific Advisory Board.

Cellastra focuses on the emergent commercial space around human regenerative medicines that stem from revolutionary discoveries of the ability of cells to regenerate and repair tissues or organs and novel pioneering techniques that are being developed in the world’s leading research institutions. Dr. Karl Mettinger, Co-founder, President and CEO, notes that “With these appointments we have three new members of our leadership that are industry or academic research veterans with a long and successful track record of developing innovative product candidates to meet unmet needs in areas of regenerative medicine including transplantation, tissue repair, and wound healing.

I am delighted to join the Cellastra to help building a world-class company. I also welcome the opportunity to help strengthen active collaborations between high tech, life science and government agencies in the US and globally,” said Dr. Kulmala. “We look forward to working together with our new team members to become a leader in cellular therapeutics and regenerative medicine,” said Dr. Alan Lewis, Chairman of Cellastra’s Board of Directors.

Dr Henrik (“Hank”) Kulmala has a long and distinguished career in the global life science industry for more than 30 years He has worked closely with FDA and International regulatory agencies as a principal on numerous marketing applications (NDAs/MAAs) and INDs, involving some 75 drugs in various therapeutic areas. He joined the pharmaceutical industry as a medical/ regulatory writer at Marion Merrell Dow in Cincinnati. He became Manager of Technical Composition at the R&D Operations of Fujisawa USA, Inc. Astellas), where he was responsible for the NDA for Prograf (tacrolimus), a multibillion dollar drug in liver transplantation. Dr. Kulmala served as Vice President Regulatory Affairs Quark Pharmaceuticals and Genix Therapeutics. For more than 20 years he has served as a consultant in areas of Product Development/ Regulatory Affairs, After earning a doctorate at The University of Chicago in Pharmacological & Physiological Sciences he served as an Assistant Professor of Pharmacology at Northeastern Ohio University College.

Professor Folke Sjoberg Professor Sjoberg is a world-renowned, leading expert in the field of burn care/wound healing/tissue repair. He is Professor of Burn Surgery/Critical Care, Department of Clinical and Experimental Medicine (IKE), Linköping University and the Burn Center, Depts. of Hand, Plastic Surgery and Intensive Care, Linköping University Hospital, Linköping, Sweden. Since 2005 he is member Executive Committee of International Society for Burn Injuries and Program Chair since 2011. From 2007 to 2009 he served as President of the European Burns Association and since 2011 he is a board member of the Verification Committee, American Burn Association. He is coauthor of more than 200 peer reviewed publications, eight books. He has supervised 40 PhD students, about 20 dissertations, and served as primary investigator of 150 clinical trials Phase 1-4. He received his MD in 1983, and PhD in 1990, both from Linkoping University. He is a prolific lecturer at conferences around the world, and serves on the editorial board of seven International Journals.

Professor Christopher Evans is a leading expert in the field of tissue repair and new treatment modalities, including gene therapy in arthritis. He is currently Director of the Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, and Professor of Orthopedics, Physical Medicine and Rehabilitation. He previously served as Director of Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, and Harvard Medical School. Dr. Evans holds a bachelor's degree in genetics and microbiology, a Ph.D. in biochemistry from the University of Wales, a master's degree in history and philosophy of science from the University of Pittsburgh, and a D.Sc. from the University of Wales. He is the author of more than 300 peer reviewed scientific publications. He served as President Orthopedic Research Society 2004 -2005, and has served as the Chair, Scientific Advisory Board, Journal of Orthopedic Research. In 2009 he won the Marshall R Urist MD Award, Orthopedic Research Society for excellence in tissue regeneration, and in 2010 the Arthur Steidler MD Award, Orthopedic Research Society for understanding of the musculoskeletal system. In 2016 he was elected an inaugural Fellow of International Orthopaedic Research (FIOR).

 

About Cellastra

Cellastra, Inc. is a San Francisco-based regenerative medicine and cellular therapeutics company focused on developing and commercializing innovative, leading proprietary technologies for multiple diseases with unmet needs. These include applications for Tissue Repair and Wound Healing. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

Cellastra, Inc. appoints new members to the Board of Directors and Management Team

August 1, 2013, San Francisco, CA -- Cellastra, Inc., a pioneering cellular therapeutics and regenerative medicine company, today announced the appointment of Daniel Quintero to the Board of Directors as General Counsel and Corporate Secretary, and Virginia Fennerty-Brooks to the Management Team as Vice President, Business Development. Cellastra focuses on the emergent commercial space around human regenerative medicines that stem from revolutionary discoveries of the ability of cells to regenerate and repair tissues or organs and novel pioneering techniques that are being developed in the world’s leading research institutions. Dr. Karl Mettinger, Co-founder, President and CEO, notes that “With the appointment of Dan Quintero and Virginia Fennerty-Broks we have two new members of our leadership that are industry veterans with a long and successful track record of business and corporate development in Silicon Valley based technology and innovation operations.."

"I am delighted to join the Cellastra board and am committed to help building a world-class company. I also welcome the opportunity to help strengthen active collaborations between high tech, life science and government agencies in the US and globally,” said Mr. Quintero. “We look forward to working together with our new team members to become a leader in cellular therapeutics and regenerative medicine,” said Dr. Alan Lewis, Chairman of Cellastra’s Board of Directors.

Daniel Quintero has a long and distinguished career in Silicon Valley and the Bay area. He is a Founding Partner and Managing Partner of Prometheus Partners LLP, a diverse group of accomplished former Big Law Partners and Executive In House counsel committed to supporting innovation.  Mr. Quintero was previously the General Counsel and Corporate Secretary for Sony Optiarc America Inc., where he concurrently served as Senior Managing Counsel and Director for Sony Electronics Inc. and managed Sony's Silicon Valley law department operations. His responsibilities included advising executive management and the board of directors of a multi-national corporation, and negotiating and structuring multi-million and multi-billion dollar engagements. Mr. Quintero is largely well respected for his views on innovation and technology and was named one of California’s Top 20 General Counsel by the Daily Journal in 2012. . Mr. Quintero received his undergraduate degree from the University of San Francisco (USF), and received his law degree from Berkeley Law (Boalt Hall), University of California at Berkeley.

Virginia Finnerty-Brooks is a biotech business development executive with over 18 years of experience. She joined EPL Technologies Inc. and, within eight years, was promoted to VP of Business Development and ultimately Chief Operating Officer. For 10 years she led business development efforts for Fibrogen Inc. and focused on the company’s Biomaterials programs includingg medical devices for dermatology, ophthalmology and wound healing. Most recently she had a similar position at Intrexon Corporation, a synthetic biology company utilizing proprietary technologies to enable the development of new and improved biological products. During her long tenure in the industry she introduced novel, proprietary technologies to diverse markets and sales channels, and brokered in/out licenses including pharmaceuticals, medical devices, consumer goods and agriculture. Mrs. Finnerty-Brooks obtained an MBA from St. Joseph’s University and a BA from Temple University, Philadelphia.

 

About Cellastra

Cellastra, Inc. is a San Francisco-based regenerative medicine and cellular therapeutics company focused on developing and commercializing innovative, leading proprietary technologies for multiple diseases with unmet needs. These include applications for cardiovascular, neurodegenerative diseases as well as diabetes, blood disorders, cancer, liver and kidney ailments. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

Cellastra, Inc. appoints Sven Andréasson to the Board of Directors

September 14, 2012, San Francisco, CA -- Cellastra, Inc., a pioneering cellular therapeutics and regenerative medicine company, today announced the appointment of Sven Andréasson to the Board of Directors. Cellastra focuses on the emergent commercial space around human regenerative medicines that stem from revolutionary discoveries of the ability of cells to regenerate and repair tissues or organs and novel pioneering techniques that are being developed in the world’s leading research institutions. Dr. Karl Mettinger, Co-founder, President and CEO, notes that “With the appointment of Sven Andréasson this month and Brian Lundstrom last month we have two new board members that are industry veterans with a long and successful track record of business and corporate development in translational and regenerative medicine companies."

"I am delighted to join the Cellastra board and am committed to help building a world-class company. I also welcome the opportunity to help strengthen active collaborations within biotech across the Atlantic between Sweden and California,” said Mr. Andréasson. “We look forward to working together with our new board members to become a leader in cellular therapeutics and regenerative medicine,” said Dr. Alan Lewis, Chairman of Cellastra’s Board of Directors.

Sven Andréasson has more than 30 years experience as an executive in the life science industry. He started his career at Kabi, Stockholm, where he became CEO for the German, UK and Belgian subsidiaries. He subsequently became head of the Biopharmaceutical division responsible for human growth hormones, blood plasma products, and LMW heparin/thrombolytic cardiovascular products. After the acquisition of Pharmacia in 1989 he became President of Pharmacia International in Brussels, Belgium and later Pharmacia SA, Paris, France (today part of Pfizer). From 1999 he served for nine years as the President and CEO of Active Biotech, Lund Sweden, a publicly traded company developing innovative products for autoimmune diseases including multiple sclerosis (partnered with TEVA) and for various cancers. He subsequently became CEO of Beta-Cell NV, in Brussels, a company developing cell-based treatments for diabetes. In February 2012 he became CEO of Isconova AB, a vaccine development company in Uppsala, Sweden. Sven Andréasson has an MSc in business administration and finance from the Stockholm School of Economics. He is chairman of Oil leadership AB, Stockholm, Sweden and Vice Chairman of Erytech SA, Lyon, France and chairman of XImmune AB, Lund, Sweden.

 

About Cellastra

Cellastra, Inc. is a San Francisco-based regenerative medicine and cellular therapeutics company focused on developing and commercializing innovative, leading proprietary technologies for multiple diseases with unmet needs. These include applications for cardiovascular, neurodegenerative diseases as well as diabetes, blood disorders, cancer, liver and kidney ailments. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

Cellastra, Inc., appoints Brian Lundstrom to the Board of Directors

August 24, 2012, San Francisco, CA -- Cellastra, Inc., a pioneering cellular therapeutics and regenerative medicine company, today announced the recent appointment of Brian Lundstrom to the Board of Directors. Cellastra focuses on the emergent commercial space around human regenerative medicines that stem from revolutionary discoveries of the ability of cells to regenerate and repair tissues or organs and novel pioneering techniques that are being developed in the world’s leading research institutions. Dr. Karl Mettinger, Co-founder, President and CEO, notes that “Our new board member is an industry veteran with a long track record of business and corporate development in translational and regenerative medicine companies."

"I am delighted that Cellastra is committed to continuing building a world-class team, and we look forward to working together to become a leader in cellular therapeutics and regenerative medicine,” said Dr. Alan Lewis, Chairman of Cellastra’s Board of Directors.

Brian Lundstrom has 25 years’ experience as an executive in the life science industry. He started his career with product development and clinical research for Novo Nordisk in Denmark and subsequently became head of business development and member of the executive management team with company’s US R&D unit. He was subsequently head of d business development for orphan disease company Oxford GlycoSciences (now UCB), immunology company SangStat/Genzyme (now Sanofi), and Californian-Swedish neuroscience company ACADIA. In 2009, Mr. Lundstrom became President of International Stem Cell Corporation (ISCO) with responsibility for public representation, financing and international collaborations until acquisition by a Russian entity. Mr. Lundstrom recently joined immunology company Open Monoclonal Antibody (OMT) as Chief Business Officer. He a M.Sc. degree in Biochemical Engineering from Danish Technical University and an MBA-equivalent degree International Management from Copenhagen Business School, Monterey Institute of International Studies, and Seattle University.

 

About Cellastra

Cellastra, Inc. is a San Francisco-based regenerative medicine and cellular therapeutics company focused on developing and commercializing innovative, leading proprietary technologies for multiple diseases with unmet needs. These include applications for cardiovascular, neurodegenerative diseases as well as diabetes, blood disorders, cancer, liver and kidney ailments. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

Cellastra, Inc., appoints C. Glenn Begley, MD, PhD, and Larry A. Couture, PhD, to Scientific Advisory Board

April 9, 2012, San Francisco, CA -- Cellastra, Inc., a pioneering cellular therapeutics and regenerative medicine company, today announced the recent appointments of C. Glenn Begley, MD, PhD, and Larry Couture, PhD, as Senior Clinical Advisors to the Scientific Advisory Board. Cellastra focuses on the emergent commercial space around human regenerative medicines that stem from revolutionary discoveries of the ability of cells to regenerate and repair tissues or organs and novel pioneering techniques that are being developed in the world’s leading research institutions. Dr. Karl Mettinger, Co-founder, President and CEO, notes that “Our new Senior Scientific Advisors are industry veterans with a track record of expeditiously moving innovations in science to the clinic and developing products for unmet needs. It is a great honor for us to have scientists of this caliber join the Cellastra Family."

"I am delighted that Cellastra is committed to continuing building a world-class team, and we look forward to working together to become a leader in cellular therapeutics and regenerative medicine,” said Dr. Alan Lewis, Chairman of Cellastra’s Board of Directors.

Dr. C. Glenn Begley has over 30 years’ experience of translational medicine including 10 years as Vice-President and Global Head of Hematology and Oncology at Amgen, where he was responsible for building the hematology and oncology research program and advancing 24 molecules into clinical development. Before joining Amgen in 2002, Dr. Begley also gained over 20 years of clinical experience in medical oncology and hematology. His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells and hastened hematopoietic recovery compared with bone marrow transplantation. This finding has revolutionized the approach to hematopoietic cell transplantation. He has held several academic positions including Executive Director at the Western Australian Institute of Medical Research, and Senior Principal Research Fellow and Professor of Medicine at the University of Melbourne at Walter and Eliza Hall Institute of Medical Research. He is also holds a PhD in cellular and molecular biology and has authored, more than 220 scientific publications including the biological characterization of recombinant G-CSF and GM-CSF in 1986.

Dr. Larry A. Couture has over 20 years of industry and academic experience in the translation of experimental biologics.  He joined City of Hope in 1998 as Founding Director of the Center for Biomedicine & Genetics, which has become a leading academic biologics manufacturing center, where more than 100 first-in-man viral, cell and antibody products have been produced under current good manufacturing practice (cGMP).  He is currently the Senior Vice President and Founding Director of the Center for Applied Technology Development at City of Hope overseeing Regulatory, Licensing, manufacturing, Program Management, and Quality.  Dr. Couture began his career at the NIH, involved in the first human gene therapy trials.  At Genzyme Corporation Dr. Couture was co-responsible for the first published adenovirus clinical gene therapy trial in cystic fibrosis. At Ribozyme Pharmaceuticals Inc. (RPI), he assembled a gene therapy team that initiated landmark gene therapy trials for patients with AIDS.  Dr. Couture is a current member of the FDA’s Cell and Gene Therapy Advisory Committee.  He has also served as an advisor for several venture capital firms and is currently the founder and CEO of eMTA Commons, Inc. Dr. Couture received his doctorate in immunology and microbiology from Albany Medical College in New York.

 

About Cellastra

Cellastra, Inc. is a San Francisco-based regenerative medicine and cellular therapeutics company focused on developing and commercializing innovative, leading proprietary technologies for multiple diseases with unmet needs. These include applications for cardiovascular, neurodegenerative diseases as well as diabetes, blood disorders, cancer, liver and kidney ailments. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

Cellastra, Inc., appoints Alan Lewis, PhD, to Chairman of the Board

March 24, 2012, San Francisco, CA -- Cellastra, Inc., a pioneering cellular therapeutics and regenerative medicine company, today announced the recent appointments of Alan Lewis, PhD, as Chairman of the Board.

Cellastra focuses on the emergent commercial space around human regenerative medicines that stem from revolutionary discoveries of the ability of cells to regenerate and repair tissues or organs and novel pioneering techniques that are being developed in the world’s leading research institutions.

Dr. Karl Mettinger, Co-founder, President and CEO, notes that “Our new Chairman is an industry veteran with a track record of expeditiously moving innovations in science to the clinic and developing products for unmet needs. It is a great honor for us to have a scientist and business leader of this caliber join the Cellastra Family."

"I am delighted that Cellastra is committed to continuing building a world-class team, and we look forward to working together to become a leader in cellular therapeutics and regenerative medicine,” said Dr. Lewis, Chairman of Cellastra’s Board of Directors.

Dr. Lewis has 37 years’ experience as an executive in the life science industry. He spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice President of Research, leading 550 scientists in translational research efforts including areas of diabetes, CNS, cardiovascular, inflammatory, allergy and bone metabolism diseases. He subsequently became CEO of Signal Pharmaceuticals, a drug development company that he successfully merged with Celgene and became President of Celgene’s research division in San Diego . After this success, Dr. Lewis became CEO of Novocell, Inc. (Viacyte), a diabetes stem cell company, and helped raise $27 million. He subsequently became CEO of the Juvenile Diabetes Research Foundation, the largest funding body in the world for diabetes research, which in 2010 reported revenues of $180 million. Most recently he was CEO of Ambit and helped the company raise $45 million. Dr. Lewis earned his PhD from University of Wales, Cardiff and was a research fellow at University of Guelph, Canada and a research fellow at Yale School of Medicine. He is the author of 120 manuscripts and the editor of 7 books.


Cellastra, Inc, a California Regenerative Medicine Company, appoints Additional Board and Executive Team Members

November 30, 2011, San Francisco, California-
Cellastra, Inc., a pioneering stem cell engineering and therapeutics company, today announced the appointment of David Fineman and Sam Broder, MD, to the Board of Directors and Bruce W. Jenett, of DLA Piper LLP (US), as General Counsel and Corporate Secretary.

Dr. Karl Mettinger, Co-founder, Chairman, President and CEO, notes that evidence of stem cells were first discovered 50 years ago. “It was in 1961 that Drs. Till & McCulloch, two Canadian scientists, first published their ground-breaking findings that set in motion a series of scientific discoveries around the world,” says Dr. Mettinger. “Cellastra emerges at the time when the quality of stem cells going into the clinic has become the perhaps most crucial question of the day for this emerging industry. Our immediate mission is to help provide the world’s best-quality stem cells for science-based research and industrial applications in order to speed development of cures for unmet medical needs.”

Mr. Fineman is founder, President and CEO of KineMed, located in Emeryville, California. KineMed discovers and applies biomarkers in network biology that guide drug discovery. Mr. Fineman has had multiple successes in starting and financing biomedical companies. In 1990, he co-founded SuperGen, Inc. (now Astex Pharmaceuticals, NASDAQ:ASTX). He led the SuperGen IPO in 1996 as acting chief financial officer and served as a member of Supergen’s Board for eight years. He is also co-founder of, and served as the first U.S. President of, Quark Pharmaceuticals, Inc., a privately held biotechnology company. He serves on the Board of Montigen Pharmaceuticals, a developer of anti-cancer agents. Mr. Fineman received his BA from the University of Maryland and his MA in 1972 , and completed Ph.D. coursework in 1974 in field theory at the Graduate Faculty of the New School for Social Research, where he was a University Scholar.
Dr. Sam Broder was a co-developer of some of the first effective drugs for the treatment of AIDS including zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC). In 1989, he was appointed by President Ronald Reagan as the Director of the National Cancer Institute (NCI) and oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). In 1995 Dr. Broder became Senior Vice President for Research and Development at IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics as Chief Medical Officer. Dr. Broder served with Celera for 13 years. He is currently a consultant to the biomedical industry and serves on the Board of several biotechnology companies, including Biomarker Strategies and Symphogen. Dr. Broder is a member of the Institute of Medicine of the U.S. National Academy of Sciences. He is the author of more than 300 scholarly papers, co-authored the first publication of the human genome sequence in “Science” magazine, and holds numerous patents.

Bruce W. Jenett is a -partner and Co-Chair of the Global Life Sciences Sector, of the law firm of DLA Piper LLP (US). Mr. Jenett’s practice is focused on the representation of U.S. and international business and finance clients in the life sciences industry. He is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures and mergers and acquisitions, as well as general counseling issues, representing both start-ups and large multinational corporations. Mr. Jenett is a frequent speaker on corporate and finance issues to both business and lawyer audiences. He is a member of the Board of Directors of BayBio (the Northern California life sciences industry association), and has been a member of, and was Chair of the Strategic Planning Committee of, former San Francisco Mayor Gavin Newsom's Biotech Advisory Council. Mr. Jenett is consistently ranked as a leading life sciences lawyer in California, national and international best-lawyer listings.

"We are pleased to announce these appointments in our efforts to further build a world-class team, and we look forward to working together in Cellastra’s progress in becoming a leader in regenerative medicine,” said Dr. Mettinger. Professor Outi Hovatta, Chair of Cellastra’s Scientific Advisory Board, said, “The timing is unique as our team at the Karolinska Institutet in Stockholm has taken a lead position in the manufacturing of the purest clinical grade of stem cells suitable for testing in patients and for cost-effective development of new therapeutics."


About Cellastra

Cellastra, Inc. is a San Francisco-based stem cell therapeutics company focused on developing, patenting and commercializing innovative, leading technologies for developing therapeutics and research tools based on human pluripotent/embryonic stem cells. Cellastra’s technology platform is expected to result in substantial clinical and therapeutic product market potential for multiple diseases with unmet needs, including diabetes, spinal cord injuries, Parkinson’s, multiple sclerosis, Alzheimer’s, cardiovascular and, liver disease, organ replacement, cancer, blood disorders and in other applications of tissue regeneration. Cellastra expects to be in a unique leadership position in stem cell engineering field by securing access to the highest clinical quality, xeno-free (free of animal additions and contaminations), pharmaceutical level, Good Manufacturing Practice (GMP) grade, human embryonic/pluripotent stem cell lines and related technologies and associated intellectual property. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

Dr. Karl Mettinger Appointed Chief Executive Officer, Cellastra Inc, a California Stem Cell and Regenerative Medicine Company

July 5, 2011-San Francisco, California- Cellastra Inc., a pioneering stem cell engineering and therapeutics company, today announced the appointment of Karl L. Mettinger, MD, PhD, as President and Chief Executive Officer.

Dr. Mettinger was a cofounder and has served as Chairman of the Board since the company was founded. The promotion is part of Cellastra’s strategy to work with scientific and medical leaders around the world to help expand clinical applications of pluripotent, especially embryonic stem cells.

"I am looking forward to immediately spearhead Cellastra to become a leader in providing highest quality clinical grade human embryonic stem cells for new therapeutics and research tools. The timing is unique as Cellastra’s Scientific Advisory Board Chair, Professor Outi Hovatta and her team at the Karolinska Institutet in Stockholm, has taken a lead position in clinical grade manufacturing."
Dr. Mettinger is a biotech industry executive with more than 26 years' experience with successful development of new therapeutics including a number of oncology, hematology, cardiovascular and CNS drugs/biologics approved by the FDA, European Medicines Agency and worldwide regulatory agencies. He is based in the US since 1989 and in the Bay Area since 2000. Between 2005-2011 served as the Chief Medical Officer of Oncolytics Biotech Inc, AB (NASDAQ:ONCY, TSX:ONC). He was Medical Director, Hematology and became Deputy General Manager, Cardiovascular, Kabi (Pharmacia AB, now part of Pfizer), Sweden, 1985-89, Medical Director/ Executive Director with IVAX new drug subsidiaries (now part of TEVA Pharmaceuticals Ltd), Miami, 1989-2000, and Chief Medical Officer/ Senior Vice President, SuperGen, Inc (now Astex, NASDAQ:ASTX), Dublin, California, 2000-2005.

Dr. Mettinger received his MD from University of Lund, Sweden and PhD in the field of Hematology/Stroke from the Karolinska Institute/Hospital, Stockholm, where he was a physician/associate professor 1974-89. He is board certified in Clinical Neurology and was Co-Founder/ President of the Swedish Stroke Society, a patient and research support organization, founded in 1983 under the auspices of Swedish Queen Silvia with today more than 10,000 members.

 

About Cellastra

Cellastra Inc. is a San Francisco-based stem cell therapeutics company focused on developing, patenting and commercializing innovative, leading technologies for developing therapeutics and research tools based on human pluripotent/embryonic stem cells. Cellastra’s technology platform is expected to result in substantial clinical and therapeutic product market potential for multiple diseases with unmet needs, including diabetes, spinal cord injuries, Parkinson’s, multiple sclerosis, Alzheimer’s, cardiovascular and, liver disease, organ replacement, cancer, blood disorders and in other applications of tissue regeneration. Cellastra expects to be in a unique leadership position in stem cell engineering field by securing access to the highest clinical quality, xeno-free (free of animal additions and contaminations), pharmaceutical level, Good Manufacturing Practice (GMP) grade, human embryonic/pluripotent stem cell lines and related technologies and associated intellectual property. See http://www.cellastra.com; for further information contact Karl L. Mettinger, President & CEO, at (510)-499-6376 or at karl.mettinger@cellastra.com

 

back to top